NEW HAVEN, Conn., Nov. 8 /PRNewswire-FirstCall/ -- Achillion
Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced that it closed the
sale of an additional 675,000 shares of its common stock in connection with
the exercise of the over-allotment option granted to the underwriters of
its recent initial public offering of 4,500,000 shares of common stock.
Upon closing of the purchase of the over-allotment shares, a total of
5,175,000 shares of common stock have been sold, resulting in gross
proceeds of $59.5 million, before commissions and expenses, and net
proceeds before expenses of $55.3 million. Cowen and Company, LLC acted as
the sole book-running manager, CIBC World Markets Corp. acted as co-lead
manager and JMP Securities LLC was co-manager.
    Copies of the final prospectus relating to the offering may be obtained
from: Cowen and Company, LLC, Prospectus Department at ADP, 1155 Long
Island Avenue, Edgewood, NY 11717, (631) 254-7106.
    This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
    About Achillion
    Achillion is a biopharmaceutical company focused on the discovery,
development and commercialization of innovative treatments for infectious
diseases. Achillion is currently developing treatments for HIV infection,
chronic hepatitis C infection and serious hospital-based bacterial
infections.
    Mary Kay Fenton
    Achillion Pharmaceuticals, Inc.
    Tel. (203) 624-7000

Link to this page: